MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

UBS Global Healthcare Conference 2024

Wednesday, November 13, 2024 at 2:00 P.M. EST

The presentation will be webcast live and may be accessed .

7th Annual Evercore HealthCONx Conference

Wednesday, December 4, 2024 at 9:35 A.M. EST

Piper Sandler 36th Annual Healthcare Conference

Thursday, December 5, 2024 at 8:30 A.M. EST

The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events .

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit .

Investor Contact

Tina Ventura,

Media Contact

Christopher Frates, 



EN
06/11/2024

Underlying

MDGLMadrigal Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Madrigal Pharmaceuticals

 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmeti...

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSH...

May 10, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results ...

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marke...

May 1, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Com...

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compen...

April 29, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Resul...

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to revi...

April 18, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. ...

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer Dr. Taub’s pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Med...

April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch